Regeneron Pharmaceuticals Inc

REGN: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|K^LOCK|%QF>LOCK|fLDF^G

Regeneron Pharmaceuticals Earnings: Strong Growth and Pipeline Progress

Regeneron's second-quarter revenue grew 17% year on year and non-GAAP EPS rose 11%. Management's updated guidance ranges are in line with its previous ranges. Cemdisiran received a US target regulatory action date in November 2026 for its first approval application in generalized myasthenia gravis.

Sponsor Center